A short peptide for efficient cellular mRNA delivery: A potential application for inducing an immune response

Area of Science:

• Biotechnology
• Nanomedicine
• Molecular Biology

Background:

• Nucleic acid therapies, including small interfering RNA (siRNA) and messenger RNA (mRNA), are promising therapeutic modalities.
• Current delivery systems often rely on complex lipid nanoparticle formulations for intracellular delivery.
• The WRAP5 peptide offers a simplified approach to nanoparticle formulation for nucleic acid delivery.

Purpose of the Study:

• To evaluate the efficacy of the WRAP5 peptide for transfecting messenger RNAs (mRNAs) of varying sizes.
• To assess the potential of WRAP5-based nanoparticles in promoting protein expression from delivered mRNAs.
• To investigate the stability and in vivo immunogenicity of WRAP5-mRNA nanoparticles.

Main Methods:

• Formulation of peptide-based nanoparticles using the WRAP5 peptide and nucleic acids (siRNA and mRNA).
• Characterization of nanoparticle size (60-80 nm) and stability under storage conditions (4°C).
• In vitro transfection and protein expression assays, and in vivo immunogenicity studies.

Main Results:

• WRAP5 peptide efficiently formed nanoparticles (60-80 nm) for nucleic acid delivery.
• Demonstrated dose-response reduction in targeted protein levels for siRNA delivery.
• Achieved successful mRNA transfection and subsequent protein expression in vitro.
• Peptide-based nanoparticles exhibited long-term stability at 4°C, retaining transfection properties for months.
• In vivo studies confirmed the induction of an immune response against the synthesized protein.

Conclusions:

• The WRAP5 peptide provides a simplified and effective method for formulating stable nanoparticles for nucleic acid delivery.
• WRAP5-based nanoparticles are suitable for both siRNA-mediated gene silencing and mRNA-mediated protein expression and vaccination.
• This peptide-based system holds potential for therapeutic applications, including immunotherapeutic vaccination.